Magenta Elevate™ study for cardiogenic shock
Part of Heart & circulation clinical trials.
This trial tests a new heart pump called the Magenta Elevate™ to help people whose heart suddenly stops pumping enough blood (cardiogenic shock). It aims to improve blood flow and reduce strain on the heart.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been in cardiogenic shock for less than 24 hours.
- Your heart's pumping ability is between 15% and 45%.
- The right side of your heart is working well or only mildly affected.
- You are not having other causes of shock like severe infection or blood clot in the lungs.
- You do not have a recent stroke or serious bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a device that helps the heart pump blood when it is too weak to do so, even with medicine, after surgery, or while waiting for a transplant. It aims to see if it's safe and works well.
This trial tests whether using a small mechanical pump inside the heart plus careful monitoring with a special catheter can help people in shock after a heart attack. It compares this approach to standard care, aiming to improve survival and recovery.
This trial is testing whether a temporary heart pump (Impella) can help people with severe heart failure and cardiogenic shock (when the heart can't pump enough blood). The goal is to see if this device can reduce fluid buildup and improve blood flow, but it's for people who are very ill and need extra support.
This trial tests a new heart pump device (CorVad) to support the heart in people who are in cardiogenic shock after a heart attack. It may help stabilize blood pressure and improve blood flow, potentially giving the heart time to recover.
This study is testing a device called an intra-aortic balloon pump (a small balloon placed in your heart's main artery to help it pump) for people in the early stages of cardiogenic shock, a condition where the heart can't pump enough blood. The goal is to see if adding this supportive device early on improves outcomes for patients with heart attacks or other heart problems.
This trial tests if unloading the heart during ECMO support helps patients recover better from cardiogenic shock. It compares different ways to reduce the heart's workload.
Hear when a new Cardiogenic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.